Transcatheter arterial chemoembolization combined with percutaneous microwave ablation for the treatment of intermediate-advanced hepatocellular carcinoma：analysis of prognostic factors in 64 cases
10.3969/j.issn.1008-794X.2014.06.005
- VernacularTitle:经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析
- Author:
Haoguang WAN
;
Wei XU
;
Hao XU
;
Yuming GU
;
Maoheng ZU
;
Yong WANG
;
Yingying ZONG
- Publication Type:Journal Article
- Keywords:
carcinoma,hepatocellular;
chemoembolization;
microwave ablation;
prognosis
- From:
Journal of Interventional Radiology
2014;(6):477-481
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prognostic factors affecting the outcome of patients with intermediate-advanced hepatocellular carcinoma (HCC) receiving transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave ablation (MWA). Methods During the period from January 2011 to July 2012 at authors’ hospital, a total of 64 patients with intermediate-advanced HCC were treated with TACE together with MWA. Fourteen potential variables which might affect the prognosis were colleted and were retrospectively analyzed. Kaplan-Meier model and log-rank test were used for single factor analysis, while Cox regression model was used for multiple factor analysis. Results The one-year, 1.5-year and 2-year overall survival rates were 75.8%, 48.4% and 33.9%, respectively. Single factor analysis and Cox regression analysis indicated that six factors, i.e. tumor size, number of tumors, portal vein tumor thrombus, serum α-fetoprotein level, tumor staging and oral administration of sorafenib, bore a relationship to the prognosis. Conclusion The tumor size, number of tumors, portal vein tumor thrombus, serum α-fetoprotein level and tumor staging are risk factors influencing the results of interventional comprehensive therapy , while oral administration of sorafenib is a protective factor for the prognosis.
